Improved quality of life with home therapy with subcutaneous immunoglobulins for patients with secondary hypogammaglobulinaemia

Improved quality of life with home therapy with subcutaneous immunoglobulins for patients with secondary hypogammaglobulinaemia

Bibliographic Details
Main Authors:	Levasseur Marie-Claude, Haddad Élie
Format:	Article
Language:	English
Published:	BMC 2012-11-01
Series:	Allergy, Asthma & Clinical Immunology

Similar Items

Treatment costs associated with hospital-based intravenous immunoglobulin therapy compared to home-based subcutaneous immunoglobulin therapy in a cohort of paediatric patients with primary immunodeficiency
by: Ducruet Thierry, et al.
Published: (2011-11-01)

Good's syndrome: Thymoma with hypogammaglobulinaemia
by: Anoop Mathew, et al.
Published: (2020-01-01)

Experience with subcutaneous immunoglobulin therapy in two pediatric cases of immune thrombocytopenia purpura
by: Chapdelaine H, et al.
Published: (2012-11-01)

Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies.
by: Francesco Cinetto, et al.
Published: (2021-01-01)

Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency
by: Hoffmann F, et al.
Published: (2010-06-01)

Health-related quality of life in patients with common variable immunodeficiency switching from intravenous to subcutaneous immunoglobulin therapy
by: Mona Al-Ahmad, et al.
Published: (2017-01-01)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
by: Suzanne Skoda-Smith, et al.
Published: (2009-12-01)

The level of myeloid-derived suppressor cells positively correlates with regulatory T cells in the blood of children with transient hypogammaglobulinaemia of infancy
by: Izabela Siemińska, et al.
Published: (2018-12-01)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
by: Kobrynski L
Published: (2012-08-01)

Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment
by: Espanol T, et al.
Published: (2014-05-01)

Switch from intravenous to subcutaneous immunoglobulin in CIDP and MMN: improved tolerability and patient satisfaction
by: Robert D. M. Hadden, et al.
Published: (2015-01-01)

Switch from intravenous or intramuscular to subcutaneous hepatitis B immunoglobulin: effect on quality of life after liver transplantation
by: Riccardo Volpes, et al.
Published: (2020-04-01)

Chapter Flow Based Enumeration of Plasmablasts in Peripheral Blood After Vaccination as a Novel Diagnostic Marker for Assessing Antibody Responses in Patients with Hypogammaglobulinaemia
by: Thon, Vojtěch
Published: (2012)

Chapter Flow Based Enumeration of Plasmablasts in Peripheral Blood After Vaccination as a Novel Diagnostic Marker for Assessing Antibody Responses in Patients with Hypogammaglobulinaemia
Published: (2012)

Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.
by: Clémence Perraudin, et al.
Published: (2020-01-01)

Subcutaneous immunoglobulin in treating inflammatory neuromuscular disorders
by: Min-Suk Yoon, et al.
Published: (2015-07-01)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
by: Jolles S
Published: (2013-09-01)

Immunoglobulin replacement therapy in secondary hypogammaglobulinemia
by: Nicolò eCompagno, et al.
Published: (2014-12-01)

Maintenance therapy with subcutaneous immunoglobulin in a patient with immune‐mediated neuropathic postural tachycardia syndrome
by: Kalliopi Pitarokoili, et al.
Published: (2021-01-01)

Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study.
by: P R Bourque, et al.
Published: (2016-01-01)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
by: Philipp Scheuerlein, et al.
Published: (2018-07-01)

Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies
by: Verena I. Leussink, et al.
Published: (2016-07-01)

Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
by: Edina Kovács, et al.
Published: (2017-11-01)

Outcome evaluation of a subcutaneous immunoglobulin clinical management program
by: Julia Zhu, et al.
Published: (2019-01-01)

Scleromyxedema with Subcutaneous Nodules: Successful Treatment with Thalidomide and Intravenous Immunoglobulin
by: M. Dolenc-Voljč, et al.
Published: (2013-11-01)

Long-term treatment with subcutaneous immunoglobulin in multifocal motor neuropathy
by: Luca Gentile, et al.
Published: (2021-04-01)

Immunoglobulin Therapy and Primary Immunodeficient Patients' Health-Related Quality of Life and Well-Being
by: Heckman, Niedre
Published: (2018)

Association of subcutaneous testosterone pellet therapy with developing secondary polycythemia
by: Katherine Lang Rotker, et al.
Published: (2018-01-01)

Economic benefit of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency
by: Martin Adriana, et al.
Published: (2012-11-01)

Clinical Practice Guidelines for Home Management of Intravenous Immunoglobulin Therapy
by: Taylor, Rosemary
Published: (2019)

High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis
by: Cherin Patrick, et al.
Published: (2014-01-01)

Subcutaneous immunoglobulin in primary immunodeficiency – impact of training and infusion characteristics on patient-reported outcomes
by: R. Mallick, et al.
Published: (2020-08-01)

Evaluation of safety and efficacy of a 20% Subcutaneous Immunoglobulin (Hizentra™), after a dose equivalent switch from intravenous or subcutaneous replacement therapy in a cohort of primary immunodeficient patients
by: Martin Adriana, et al.
Published: (2012-11-01)

Life-threatening hemorrhage following subcutaneous heparin therapy
by: Jana Hudcova, et al.
Published: (2008-12-01)

Subcutaneous Immunoglobulin-G Replacement Therapy with Preparations Currently Available in the United States for Intravenous or Intramuscular Use: Reasons and Regimens
by: Chouksey Akhilesh, et al.
Published: (2005-09-01)

Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases
by: Patrick Cherin, et al.
Published: (2015-11-01)

Corrigendum to “High-Dose Subcutaneous Immunoglobulins for the Treatment of Severe Treatment-Resistant Polymyositis”
by: Patrick Cherin, et al.
Published: (2015-01-01)

Intravenous immunoglobulin therapy in Morvan syndrome secondary to recurrent thymic carcinoma
by: Gabriel Horta Baas
Published: (2015-12-01)

Passive blood anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction
by: Przemyslaw Zdziarski, et al.
Published: (2017-09-01)

Anti-human immunoglobulin G antibody production in rabbits: Comparison of intramuscular and subcutaneous methods
Published: (2014-01-01)